Evaluation of Efficacy of Ophthalmic Solution in Seasonal Allergic Conjunctivitis

A Multi-Center, Randomized, Double-Masked Parallel Group Study Evaluating the Efficacy, Safety, and QOL of R89674 0.25% Ophthalmic Solution Compared to Vehicle or an Active Control in a Modified Model of Environmental Seasonal Allergic Conjunctivitis

The purpose of this summary is to evaluate the efficacy and safety of R89674 0.025% ophthalmic solution compared with placebo or an active control in subjects with seasonal allergic conjunctivitis

Inclusion Criteria:

• history of positive diagnostic test for ragweed within the past 2 years;
• positive bilateral response to ragweed as induced by conjunctival allergen challenge

Exclusion Criteria:

• ocular infection;
• history of retinal detachment, diabetic neuropathy, or any progressive retinal disease;
• moderate to severe asthma;
• dry eye syndrome;
• history of severe, unstable, or uncontrolled cardiovascular, pulmonary, hepatic, renal or autoimmune disease;
• pregnancy or lactation